Targeting Glucose Metabolism in Cancer Immunotherapy: A Promising Avenue for Enhanced Treatment Strategies

Christina Zhang

doi:10.54097/ns9brk94

Authors

Christina Zhang

DOI:

https://doi.org/10.54097/ns9brk94

Keywords:

cancer immunotherapy; glucose metabolism; glycolysis.

Abstract

Cancer immunotherapy has emerged as an innovative strategy for treating multiple types of cancer. Recent breakthroughs have emphasized the significance of altering glucose metabolism in malignant cells; specifically, the heightened dependency of cancer cells on glucose metabolism (“Warburg effect”), where cancer cells alter their metabolic pathway so that they utilize glucose as an energy source, even when oxygen is present. This adaptation allows for rapid tumor cell proliferation, enabling them to grow and divide at an accelerated pace. Current research concentrates on the development of cancer treatments aimed at inhibiting glucose metabolism in cancer cells. This approach aims to improve the effectiveness of existing immunotherapies by utilizing the metabolic pathways of malignant cells through direct and indirect inhibition of glycolysis. This review discusses the interplay between glucose metabolism and immune response, explores current efforts in manipulating glucose metabolism for therapeutic benefits, and provides insights into future directions for optimizing this strategy.

Downloads

Download data is not yet available.

References

Liu, Y. X., Feng, J. Y., Sun, M. M., et al. Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism. Acta Pharmacologica Sinica, 2019, 40(1): 122–132.

Li, X., Wenes, M., Romero, P., et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nature reviews. Clinical oncology, 2019, 16(7): 425–441.

Chapman, N. M., Boothby, M. R., Chi, H. Metabolic coordination of T cell quiescence and activation. Nature reviews. Immunology, 2020, 20(1): 55–70.

Rivadeneira, D. B., Delgoffe, G. M. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research, 2018, 24(11): 2473–2481.

Shi, L. Z., Wang, R., Huang, G., et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. The Journal of Experimental Medicine, 2011, 208(7): 1367–1376.

Estrella, V., Chen, T., Lloyd, M., et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer research, 2013, 73(5): 1524–1535.

Sukumar, M., Liu, J., Ji, Y., et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. The Journal of Clinical Investigation, 2013, 123(10): 4479–4488.

Vella, S., Conti, M., Tasso, R., et al. Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells. International Journal of Cancer, 2012, 130(7): 1484–1493.

Jena, B., Rushworth, D., McNamara, G. T., et al. Mitochondrial Biomass As a Measure of Fitness for T Cells Expressing Chimeric Antigen Receptors. Blood, 2015, 126(23): 3242–3242.

Sukumar, M., Liu, J., Mehta, G. U., et al. Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metabolism, 2016, 23(1): 63–76.

Ron-Harel, N., Santos, D., Ghergurovich, J. M., et al. Mitochondrial Biogenesis and Proteome Remodeling Promote One-Carbon Metabolism for T Cell Activation. Cell Metabolism, 2016, 24(1): 104–117.

Buck, M. D., O'Sullivan, D., Klein Geltink, R. I., et al. Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. Cell, 2016, 166(1): 63–76.

Zhou, Y., Guo, Y., Tam, K. Y. Targeting glucose metabolism to develop anticancer treatments and therapeutic patents. Expert opinion on therapeutic patents, 2022, 32(4): 441–453.

Gong, Y., Ji, P., Yang, Y. S., et al. Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell Metabolism, 2021, 33(1): 51–64.e9.

Renner, K., Bruss, C., Schnell, A., et al. Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy. Cell Reports, 2019, 29(1): 135–150.e9.

El Hassouni, B., Granchi, C., Vallés-Martí, A., et al. The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies. Seminars in Cancer Biology, 2020, 60, 238–248.

Boudreau, A., Purkey, H. E., Hitz, A., et al. Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nature Chemical Biology, 2016, 12(10): 779–786.

Talekar, M., Boreddy, S. R., Singh, A., et al. Tumor aerobic glycolysis: new insights into therapeutic strategies with targeted delivery. Expert opinion on biological therapy, 2014, 14(8): 1145–1159.

Polet, F., Feron, O. Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. Journal of Internal Medicine, 2013, 273(2): 156–165.

Reckzeh, E. S., Karageorgis, G., Schwalfenberg, M., et al. Inhibition of Glucose Transporters and Glutaminase Synergistically Impairs Tumor Cell Growth. Cell Chemical Biology, 2019, 26(9): 1214–1228.e25.

Shenoy, N., Creagan, E., Witzig, T., et al. Ascorbic acid in cancer treatment: let the phoenix fly. Cancer Cell, 2018, 34(5): 700–706.

de Padua, M. C., Delodi, G., Vučetić, M., et al. Disrupting glucose-6-phosphate isomerase fully suppresses the "Warburg effect" and activates OXPHOS with minimal impact on tumor growth except in hypoxia. Oncotarget, 2017, 8(50): 87623–87637.

Kumar, A., Vishvakarma, N. K., Tyagi, et al. Anti-neoplastic action of aspirin against a T-cell lymphoma involves an alteration in the tumour microenvironment and regulation of tumour cell survival. Bioscience Reports, 2012, 32(1): 91–104.